Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Virally Suppressed People With HIV and Obesity
NCT07707778Phase 4Enrolling by invitation
- Sponsor
- National Taiwan University Hospital Clinical Trial Center
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirzepatide in obesity, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD) and 2 more (2 arms), sponsored by National Taiwan University Hospital Clinical Trial Center. Primary endpoints: Second generation epigenetic aging clock at 57 weeks and Third generation epigenetic aging clock at 57 weeks. Started Jun 2026; status: enrolling by invitation.
02
Drugs
03
Conditions
obesitymetabolic syndromemetabolic dysfunction-associated steatotic liver disease (MASLD)dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07707778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707778.